CT 定量肝脏表面结节度:用于检测门静脉高压的效用
本研究为回顾性研究,纳入训练队列 189 例和外部验证队列 78 例肝硬化患者,均行腹部 CT 和肝静脉压力梯度测量。肝脏表面结节度(LSN)评分与肝静脉压力梯度相关(r=0.75),诊断临床显著门静脉高压的 AUROC 在训练队列为 0.88、验证队列为 0.87,优于其他多种无创检测。
要点
- LSN 评分与 HVPG 相关(r=0.75;P<.001),可用于无创评估门静脉高压。
- LSN 评分 cutoff 2.8 时,训练队列阳性预测值 88%,验证队列 86%。
- LSN 诊断临床显著门静脉高压的 AUROC 训练队列 0.88、验证队列 0.87。
核心结论
- 基于 CT 的 LSN 评分对检测临床显著门静脉高压表现出高诊断效能,并优于多种其他无创检测。
研究设计与样本
- 回顾性研究,训练队列 n=189、外部验证队列 n=78,均为 2010 至 2016 年间接受腹部 CT 和肝静脉压力梯度测量的肝硬化患者。
- 以 HVPG 测量为参考标准,从 CT 图像和血清实验室指标衍生 LSN 评分、肝脾体积、肝脾体积比、血小板计数与脾直径比值、Iranmanesh 评分、AST 与血小板比值指数及 Fibrosis-4 指数。
- 采用 AUROC 评估各检测预测临床显著门静脉高压的准确性,并用 DeLong 检验比较;使用 Student t 检验和 Pearson 相关系数。
关键影像表现/征象
- 临床显著门静脉高压患者 LSN 评分高于无临床显著门静脉高压者(3.2±0.6 vs 2.4±0.3;P<.001)。
诊断标准与关键数值
- LSN 评分 cutoff 2.8 对临床显著门静脉高压的阳性预测值在训练队列为 88%,在验证队列为 86%。
- LSN 评分诊断临床显著门静脉高压的 AUROC 在训练队列为 0.88±0.03,在验证队列为 0.87±0.04。
- LSN 评分高于其他可用无创检测(DeLong 检验,所有 P<.001)。
- LSN 评分与 HVPG 相关(r=0.75;P<.001)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To determine whether quantification of liver surface nodularity (LSN) provides an estimate of the presence of clinically significant portal hypertension (CSPH) in patients with cirrhosis. Materials and Methods This retrospective study included a training cohort (n = 189) and separate external validation cohort (n = 78), both composed of patients with cirrhosis who underwent abdominal CT and hepatic venous pressure gradient (HVPG) measurement between 2010 and 2016. The LSN score, liver and spleen volumes, liver-to-spleen volume ratio, platelet count to spleen diameter ratio, Iranmanesh score, aspartate amino transferase-to-platelet ratio index, and Fibrosis-4 index were derived from CT images and serum laboratories. The accuracy of the various tests for predicting CSPH was evaluated with area under the receiver operating characteristic curve (AUROC) and compared by using the DeLong test. Student t test and Pearson correlation coefficient were used. Results One hundred eighty-nine patients were analyzed (119 men [mean age ± standard deviation, 57 years ± 11; range, 29-81 years] and 70 women [mean age, 61 years ± 10; range, 34-83 years]; overall mean age, 58 years ± 10; range, 29-83 years). A total of 102 patients (54%) had CSPH. LSN score correlated with HVPG (r = 0.75; P < .001). Patients with CSPH had a higher LSN score than did those without CSPH (3.2 ± 0.6 vs 2.4 ± 0.3; P < .001). A cutoff value of 2.8 had a positive predictive value of 88% for CSPH; the AUROC of LSN was 0.88 ± 0.03. This was higher than that of other available noninvasive tests (DeLong, all P < .001). In the validation cohort, LSN score of 2.8 had a positive predictive value of 86% for CSPH; the AUROC was 0.87 ± 0.04. Conclusion The CT-based liver surface nodularity score demonstrated high diagnostic performance for detecting clinically significant portal hypertension and outperformed multiple other noninvasive tests. © RSNA, 2018 Online supplemental material is available for this article.
引用
- Sartoris R, Rautou PE, Elkrief L, et al. Quantification of Liver Surface Nodularity at CT: Utility for Detection of Portal Hypertension. Radiology. 2018. PMID: 30179109. doi:10.1148/radiol.2018181131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。